Goodwill
£000
Software
£000
Development
costs
£000
Patent
rights
£000
Marketing
authorisations
£000
Acquired
intangibles
£000
Total
£000
Cost
At 1 July 201358,3553,4129,0713,680853204,830280,201
Additions1,3811,0652,446
Acquisitions through business combinations847,4837,567
Foreign exchange adjustments (restated)*(3,461)794(359)(14,165)(17,191)
At 30 June 2014 and 1 July 201454,9785,5879,7773,680853198,148273,023
Additions6431,0351,678
Disposals(52)(86)(138)
Foreign exchange adjustments(5,652)(515)(86)(12,534)(18,787)
At 30 June 201549,3265,66310,6403,680853185,614255,776
Amortisation
At 1 July 20139473,9631,46854,22760,605
Charge for the year3411,12233416,54318,340
Foreign exchange adjustments (restated)*981(292)(2,793)(2,104)
At 30 June 2014 and 1 July 20142,2694,7931,80267,97776,841
Charge for the year18773233617,87119,126
Disposals(52)(41)(93)
Foreign exchange adjustments(178)(186)(6,418)(6,782)
At 30 June 20152,2265,2982,13879,43089,092
Net book value
At 30 June 201549,3263,4375,3421,542853106,184166,684
At 30 June 2014 and 1 July 201454,9783,3184,9841,878853130,171196,182
At 30 June 201358,3552,4655,1082,212853150,603219,596
2015
£000
2014
£000
Contracted capital commitments
Software assets in the course of construction included above1,1212,856

*The opening cost and accumulated amortisation balances have been restated to reflect the foreign exchange separately on each element. This has no impact on the opening net book value.

Goodwill is allocated across cash generating units that are expected to benefit from that business combination. Key assumptions made in this respect are given in note 13.

In accordance with the disclosure requirements of IAS 38 'Intangible Assets', the components of acquired intangibles are summarised below:

Acquired
development
costs
£000
Product
rights
£000
Total
£000
Cost
At 1 July 201324,920179,910204,830
Acquisitions through business combinations7,4837,483
Foreign exchange adjustments (restated)*(1,583)(12,582)(14,165)
At 30 June 2014 and 1 July 201423,337174,811198,148
Foreign exchange adjustments(2,618)(9,916)(12,534)
At 30 June 201520,719164,895185,614
Amortisation
At 1 July 20132,24351,98454,227
Charge for the year2,19114,35216,543
Foreign exchange adjustments (restated)*(2,793)(2,793)
At 30 June 2014 and 1 July 20144,43463,54367,977
Charge for the year2,23315,63817,871
Foreign exchange adjustments(658)(5,760)(6,418)
At 30 June 20156,00973,42179,430
Net book value
At 30 June 201514,71091,474106,184
At 30 June 2014 and 1 July 201418,903111,268130,171
At 30 June 201322,677127,926150,603

*The opening cost and accumulated amortisation balances have been restated to reflect the foreign exchange separately on each element. This has no impact on the opening net book value.

The amortisation charge is recognised within administrative expenses in the Consolidated Income Statement

The principal assets within acquired intangibles are the development costs and product rights recognised on the acquisitions of Dechra Veterinary Products Holding A/S, DermaPetInc., Genitrix®Limited and Eurovet Animal Health B.V. The carrying value of these assets at 30 June 2015 was £92.0 million with a remaining amortisation period of 2½ years, 10½ years, 5½ years and 7 years respectively. The other significant assets within acquired intangibles are the product rights recognised on the acquisition of Pharmaderm Animal Health and HY-50. The carrying values at 30 June 2015 were £1.2 million and £3.4 million with a remaining amortisation period of 8 years and 6½ years respectively.

In May 2014, the Company completed the purchase of product rights to Phycox, a patented nutraceutical now launched, called Levocrine, which competes in the US veterinary joint health supplement market, as well as a new product in the final phase of development. The carrying value of these assets at 30 June 2015 is £6.6 million, with a remaining amortisation period of 9 years.

The Company previously completed a licensing, supply and distribution agreement for a branded veterinary generic pharmaceutical product from a US pharmaceutical development company. Under the terms of the agreement, Dechra paid US$1.5 million upon signing and will pay a further US$1.5 million on approval. There is a potential further contingent payment of US$2.0 million based on achieving US$20.0 million cumulative sales.

The principal asset within patent rights comprises payments to acquire the right to develop and market Trilostane, the active ingredient of Vetoryl Capsules, for animal health applications in the USA and Canada. The carrying value at 30 June 2015 was £0.8 million with a remaining amortisation period of 3½ years. The rights to Equidone®, which was launched in the US during 2011, have a carrying value of £0.6 million with an amortisation period of 6 years.

£0.8 million of the marketing authorisations relate to the Vetivex range of products. The Vetivex marketing authorisations are regarded as having indefinite useful economic lives and have not been amortised. Ownership of the marketing authorisations rests with the Group in perpetuity. There are not believed to be any legal, regulatory or contractual provisions that limit their useful lives. Vetivex is an established range of products which are relatively simple in nature and there are a limited number of players in the market. Accordingly, the Directors believe that it is appropriate that the marketing authorisations are treated as having indefinite lives for accounting purposes.